UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $437.80 Million Stock Holdings in Agilent Technologies, Inc. (NYSE:A)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in Agilent Technologies, Inc. (NYSE:A) by 4.8% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 2,948,536 shares of the medical research company’s stock after buying an additional 136,184 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned approximately 1.03% of Agilent Technologies worth $437,799,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also bought and sold shares of the company. Massachusetts Financial Services Co. MA increased its position in shares of Agilent Technologies by 5.7% during the 2nd quarter. Massachusetts Financial Services Co. MA now owns 15,064,660 shares of the medical research company’s stock worth $1,952,832,000 after purchasing an additional 809,149 shares during the last quarter. FMR LLC increased its position in shares of Agilent Technologies by 62.2% during the 3rd quarter. FMR LLC now owns 1,287,665 shares of the medical research company’s stock worth $191,193,000 after purchasing an additional 493,947 shares during the last quarter. Marshall Wace LLP boosted its stake in shares of Agilent Technologies by 48.6% during the 2nd quarter. Marshall Wace LLP now owns 957,128 shares of the medical research company’s stock worth $124,073,000 after acquiring an additional 313,155 shares during the period. Jennison Associates LLC boosted its stake in shares of Agilent Technologies by 63.3% during the 3rd quarter. Jennison Associates LLC now owns 586,439 shares of the medical research company’s stock worth $87,075,000 after acquiring an additional 227,431 shares during the period. Finally, Impax Asset Management Group plc boosted its stake in shares of Agilent Technologies by 8.2% during the 3rd quarter. Impax Asset Management Group plc now owns 2,667,616 shares of the medical research company’s stock worth $396,088,000 after acquiring an additional 203,234 shares during the period. Institutional investors and hedge funds own 87.42% of the company’s stock.

Insider Activity

In related news, SVP Dominique Grau sold 9,990 shares of the company’s stock in a transaction dated Thursday, September 26th. The stock was sold at an average price of $145.00, for a total transaction of $1,448,550.00. Following the sale, the senior vice president now owns 40,011 shares in the company, valued at $5,801,595. This represents a 19.98 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 0.33% of the company’s stock.

Agilent Technologies Price Performance

Shares of A opened at $138.14 on Friday. Agilent Technologies, Inc. has a 12-month low of $124.10 and a 12-month high of $155.35. The business has a 50-day simple moving average of $137.65 and a two-hundred day simple moving average of $137.44. The company has a quick ratio of 1.37, a current ratio of 1.78 and a debt-to-equity ratio of 0.36. The stock has a market cap of $39.69 billion, a PE ratio of 28.66, a PEG ratio of 5.91 and a beta of 1.07.

Agilent Technologies Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, January 22nd. Stockholders of record on Tuesday, December 31st will be paid a $0.248 dividend. This is a boost from Agilent Technologies’s previous quarterly dividend of $0.24. The ex-dividend date is Tuesday, December 31st. This represents a $0.99 annualized dividend and a dividend yield of 0.72%. Agilent Technologies’s dividend payout ratio is presently 20.54%.

Analyst Ratings Changes

A has been the subject of several research analyst reports. Evercore ISI lifted their target price on Agilent Technologies from $135.00 to $145.00 and gave the stock an “in-line” rating in a research note on Tuesday, October 1st. Barclays reduced their price target on Agilent Technologies from $145.00 to $135.00 and set an “underweight” rating for the company in a research note on Wednesday. TD Cowen boosted their price target on Agilent Technologies from $153.00 to $160.00 and gave the company a “buy” rating in a research note on Thursday, August 22nd. UBS Group boosted their price target on Agilent Technologies from $141.00 to $150.00 and gave the company a “neutral” rating in a research note on Thursday, August 22nd. Finally, Stifel Nicolaus restated a “buy” rating and issued a $151.00 price target on shares of Agilent Technologies in a research note on Monday, August 26th. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating and eight have given a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $143.40.

Agilent Technologies Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.